240 related articles for article (PubMed ID: 7537967)
1. A comparative review of the adverse effect profiles of heparins and heparinoids.
Borris LC; Lassen MR
Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
[TBL] [Abstract][Full Text] [Related]
3. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
4. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
[No Abstract] [Full Text] [Related]
5. Danaparoid sodium.
Acostamadiedo JM; Iyer UG; Owen J
Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
Counsell C; Sandercock P
Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
[No Abstract] [Full Text] [Related]
7. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for bleeding during treatment of acute venous thromboembolism.
Wester JP; de Valk HW; Nieuwenhuis HK; Brouwer CB; van der Graaf Y; Meuwissen OJ; Hart HC; Sixma JJ; Banga JD
Thromb Haemost; 1996 Nov; 76(5):682-8. PubMed ID: 8950773
[TBL] [Abstract][Full Text] [Related]
9. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans.
Ludwig RJ; Beier C; Lindhoff-Last E; Kaufmann R; Boehncke WH
Contact Dermatitis; 2003 Sep; 49(3):158-9. PubMed ID: 14678213
[No Abstract] [Full Text] [Related]
10. [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation].
Scheffler E; Aulmann M; Remppis A; Ziegler R; Martin E; Fleischer F; Nawroth P
Z Kardiol; 1995 Jul; 84(7):565-8. PubMed ID: 7676727
[TBL] [Abstract][Full Text] [Related]
11. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
12. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
[TBL] [Abstract][Full Text] [Related]
13. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
Ramakrishna R; Manoharan A; Kwan YL; Kyle PW
Br J Haematol; 1995 Nov; 91(3):736-8. PubMed ID: 8555084
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
15. An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
Magnani HN
Thromb Res; 2010 Apr; 125(4):297-302. PubMed ID: 19656552
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].
Chirurg; 1998 Nov; 69(11 Suppl Massnahme):1-4. PubMed ID: 9853175
[No Abstract] [Full Text] [Related]
17. Low molecular weight heparins and heparinoids.
Eikelboom JW; Hankey GJ
Med J Aust; 2002 Oct; 177(7):379-83. PubMed ID: 12358583
[TBL] [Abstract][Full Text] [Related]
18. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
[TBL] [Abstract][Full Text] [Related]
19. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
[TBL] [Abstract][Full Text] [Related]
20. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
